| Cash and Cash Equivalents | 5.07M |
| Accounts Receivable, Net | 13.41M |
| Inventories, Net | 14.4M |
| Prepaid Expenses and Other | 1.45M |
| TOTAL CURRENT ASSETS | 34.34M |
| PROPERTY, PLANT & EQUIPMENT, NET | 22.13M |
| Goodwill, Intangibles and Other, Net | |
| TOTAL ASSETS | 166.25M |
| Accounts Payable | 3.48M |
| Accrued Salaries & Payroll Taxes | 3.55M |
| Notes Payable - Current Portion | |
| Revolving Line of Credit | |
| Due To Apex Laboratories, Inc. | |
| Other Accrued Expenses | 2.01M |
| Taxes Payable | |
| TOTAL CURRENT LIABILITIES | 21.79M |
| Deferred Income Taxes Payable | 4.32M |
| Notes Payable - Long Term | |
| Preferred Stock, No Par Value | |
| Common Stock, No Par Value; authorized 8,000,000 shares; issued and outstanding, 3,280,996 shares (6/30/11) and 3,250,736 shares (3/31/11) | 23.61M |
| Employee Loans to Purchase Stock | |
| Retained Earnings | 67.95M |
| TOTAL STOCKHOLDERS' EQUITY | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 166.25M |